A review of clinical and microbiological outcomes following treatment of infections involving multidrug-resistant Acinetobacter baumannii with tigecycline

Journal of Antimicrobial Chemotherapy

Volumn 63, Issue 4, 2009, Pages 775-780

  Gordon, N C ^a   Wareham, D W ^a,b,c  

^a BARTS HEALTH NHS TRUST   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c Institute of Cell and Molecular Science   (United Kingdom)

Author keywords

Glycylcyclines; Gram negative; Polymicrobial infections

Indexed keywords

AMIKACIN; CARBAPENEM; CIPROFLOXACIN; CLARITHROMYCIN; COLISTIN; COTRIMOXAZOLE; GENTAMICIN; IMIPENEM; MEROPENEM; METRONIDAZOLE; MINOCYCLINE; PIPERACILLIN PLUS TAZOBACTAM; RIFAMPICIN; SULBACTAM; TIGECYCLINE; TOBRAMYCIN; VANCOMYCIN;

ABDOMINAL INFECTION; ACINETOBACTER BAUMANNII; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTEREMIA; BACTERIAL INFECTION; BONE INFECTION; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; GRAM NEGATIVE SEPSIS; HUMAN; INFECTIOUS ARTHRITIS; LOADING DRUG DOSE; MALE; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; MULTIDRUG RESISTANCE; RESPIRATORY TRACT INFECTION; REVIEW; SEPSIS; SKIN INFECTION; SOFT TISSUE INFECTION; VENTILATOR ASSOCIATED PNEUMONIA;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; CHILD; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; GREAT BRITAIN; HUMANS; MALE; MINOCYCLINE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 62549153583     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn555     Document Type: Review

References (13)

1. Chopra I, Roberts M. Tetracycline antibiotics: Mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev 2001; 65: 232-60.
2. Bouchillon S, Hoban D, Johnson B et al. In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004). Diagn Microbiol Infect Dis 2005; 52 173-9.
3. Ellis-Grosse E, Babinchak T, Dartois N et al. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: Results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 2005; 41 Suppl 5: S341-53.
4. Oliva M, Rekha A, Yellin A et al. A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections [Study ID Numbers: 3074A1-301-WW; ClinicalTrials.gov Identifier: NCT00081744]. BMC Infect Dis 2005; 5: 88.
5. Sunenshine R, Wright M, Maragakis L et al. Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization. Emerg Infect Dis 2007; 13: 97-103.
6. Wareham DW, Bean DC, Khanna P et al. Bloodstream infection due to Acinetobacter spp.: Epidemiology, risk factors and impact of multi-drug resistance. Eur J Clin Microbiol Infect Dis 2008; 27 607-12.
7. Coelho J, Turton J, Kaufmann M et al. Occurrence of carbapenem-resistant Acinetobacter baumannii clones at multiple hospitals in London and Southeast England. J Clin Microbiol 2006; 44: 3623-7.
8. Karageorgopoulos D, Kelesidis T, Kelesidis I et al. Tigecycline for the treatment of multidrug-resistant (including carbapenemresistant) Acinetobacter infections: A review of the scientific evidence. J Antimicrob Chemother 2008; 62: 45-55.
9. Schafer J, Goff D, Stevenson K et al. Early experience with tigecycline for ventilator-associated pneumonia and bacteraemia caused by multidrug-resistant Acinetobacter baumannii. Pharmacotherapy 2007; 27: 980-7.
10. Anthony K, Fishman N, Linkin D et al. Clinical and microbiological outcomes of serious infections with multidrug-resistant Gram-negative organisms treated with tigecycline. Clin Infect Dis 2008; 46 567-70.
11. Moland E, Craft D, Hong S et al. In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii and selection of tigecycline-amikacin synergy. Antimicrob Agents Chemother 2008; 52: 2940-2.
12. Wilks M, Wilson A, Warwick S et al. Control of an outbreak of multidrug-resistant Acinetobacter baumannii-calcoaceticus colonization and infection in an intensive care unit (ICU) without closing the ICU or placing patients in isolation. Infect Control Hosp Epidemiol 2006; 27: 654-8.
13. Vasilev K, Reshedko G, Orasan R et al. A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae. J Antimicrob Chemother 2008; 62 Suppl 1: I29-40.